Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PT 2385

Next Previous
X
Search
Drug Profile

PT 2385

Alternative Names: PT2385

Latest Information Update: 02 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer National Cancer Institute (USA); Peloton Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Indenes; Small molecules
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Renal cell carcinoma

Most Recent Events

  • 27 Sep 2023 Peloton Therapeutics completes a phase-II clinical trials in Renal cell carcinoma (associated with Von Hippel Lindau disease, First-line therapy) in USA (PO) (NCT03108066)
  • 02 Jan 2023 Phase II development in Glioblastoma (Recurrent, Second-line therapy or greater) is still ongoing in USA (PO)
  • 04 Aug 2021 University of Texas Southwestern Medical Center plans a two cohort phase I trial for Renal cell carcinoma (Diagnosis) in August 2021 (Parenteral, Infusion) (NCT04989959)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top